Oxford Gene Technology (OGT) has processed more than 20,000 samples generated by the Wellcome Trust Case Control Consortium (WTCCC).
The WTCCC is the world's largest CNV study and involved a collaboration of 24 leading human geneticists.
The project analysed DNA samples from patients to identify genetic variants that play a role in various human diseases, including bipolar disorder, Crohn's disease, coronary artery disease, type 1 and 2 diabetes, rheumatoid arthritis, breast cancer and hypertension.
OGT processed the samples in 20 weeks, using automated processing to achieve exceptional data quality from whole-genome human CNV-focussed microarrays developed by Agilent.
More than 40 quality-control checks have been performed and recorded for each sample during the workflow, producing documented evidence of the excellent QC metrics that have been met.
Dr Matt Hurles, of the Wellcome Trust Sanger Institute, said: 'To characterise genetic variants, reproducible performance and reliable processing of the high-resolution microarrays are essential.
'This project demanded high quality data generated to tight deadlines.
'Our preliminary estimate is that approximately 20-30 per cent of the up to 11,000 loci targeted on the array we have designed are both polymorphic in our British study population and provide sufficient data quality to assign integer copy numbers to individuals.' OGT can provide high-quality data for a variety of high-throughput microarray applications.
It can offer a bespoke microarray service from array design and synthesis through to bioinformatics support and data analysis.
Agilent collaborated with the WTCCC and the Genome Structural Variation Consortium on the array design for this study and Agilent manufactured the microarrays at its Santa Clara, California fabrication facility.
